open access

Vol 69, No 1 (2018)
Original Paper
Published online: 2017-12-20
Submitted: 2017-07-18
Accepted: 2017-10-05
Get Citation

Discrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by mass spectrometry imaging

Anna Wojakowska, Laura M. Cole, Mykola Chekan, Katarzyna Bednarczyk, Magdalena Maksymiak, Małgorzata Oczko-Wojciechowska, Barbara Jarząb, Malcolm R. Clench, Joanna Polańska, Monika Pietrowska, Piotr Widlak
DOI: 10.5603/EP.a2018.0003
·
Pubmed: 29492952
·
Endokrynologia Polska 2018;69(1):2-8.

open access

Vol 69, No 1 (2018)
Original Paper
Published online: 2017-12-20
Submitted: 2017-07-18
Accepted: 2017-10-05

Abstract

Introduction: The distinction of papillary thyroid carcinomas from benign thyroid lesions has important implication for clinical man­agement. Classification based on histopathological features can be supported by molecular biomarkers, including lipidomic signatures, identified with the use of high-throughput mass spectrometry techniques. Formalin fixation is a standard procedure for stabilization and preservation of tissue samples, therefore this type of samples constitute highly valuable source of clinical material for retrospective molecular studies. In this study we used mass spectrometry imaging to detect lipids discriminating papillary cancer from not cancerous thyroid directly in formalin-fixed tissue sections.

Material and methods: For this purpose imaging and profiling of lipids present in non-malignant and cancerous thyroid tissue specimens were conducted. High resolution MALDI-Q-Ion Mobility-TOF-MS technique was used for lipidomic analysis of formalin fixed thyroid tissue samples. Lipids were identified by the comparison of the exact molecular masses and fragmentation pathways of the protonated molecule ions, recorded during the MS/MS experiments, with LIPID MAPS database.

Results: Several phosphatidylcholines (32:0, 32:1, 34:1 and 36:3), sphingomyelins (34:1 and 36:1) and phosphatidic acids (36:2 and 36:3) were detected and their abundances were significantly higher in cancerous tissue compared to non-cancerous tissue. The same lipid species were detected in formalin-fixed as in fresh-frozen tissue, but [M + Na]+ ions were the most abundant in formalin fixed whereas [M + K]+ ions were predominant in fresh tissue.

Conclusions: Our results prove the viability of MALDI-MSI for analysis of lipid distribution directly in formalin-fixed tissue, and the potential for their use in the classification of thyroid diseases.

Abstract

Introduction: The distinction of papillary thyroid carcinomas from benign thyroid lesions has important implication for clinical man­agement. Classification based on histopathological features can be supported by molecular biomarkers, including lipidomic signatures, identified with the use of high-throughput mass spectrometry techniques. Formalin fixation is a standard procedure for stabilization and preservation of tissue samples, therefore this type of samples constitute highly valuable source of clinical material for retrospective molecular studies. In this study we used mass spectrometry imaging to detect lipids discriminating papillary cancer from not cancerous thyroid directly in formalin-fixed tissue sections.

Material and methods: For this purpose imaging and profiling of lipids present in non-malignant and cancerous thyroid tissue specimens were conducted. High resolution MALDI-Q-Ion Mobility-TOF-MS technique was used for lipidomic analysis of formalin fixed thyroid tissue samples. Lipids were identified by the comparison of the exact molecular masses and fragmentation pathways of the protonated molecule ions, recorded during the MS/MS experiments, with LIPID MAPS database.

Results: Several phosphatidylcholines (32:0, 32:1, 34:1 and 36:3), sphingomyelins (34:1 and 36:1) and phosphatidic acids (36:2 and 36:3) were detected and their abundances were significantly higher in cancerous tissue compared to non-cancerous tissue. The same lipid species were detected in formalin-fixed as in fresh-frozen tissue, but [M + Na]+ ions were the most abundant in formalin fixed whereas [M + K]+ ions were predominant in fresh tissue.

Conclusions: Our results prove the viability of MALDI-MSI for analysis of lipid distribution directly in formalin-fixed tissue, and the potential for their use in the classification of thyroid diseases.

Get Citation

Keywords

mass spectrometry imaging, papillary thyroid carcinoma, clinical lipidomics, formalin-fixed tissue specimens

Supplementary Files (4)
Figure S1
View
370KB
Figure S2
View
758KB
Table sI. Clinical characteristics of thyroid tissue specimens used in the study
Download
46KB
Table s II. Identification of lipid molecules using MS/MS analysis of fresh frozen thyroid papillary cancer region (mass accurate measurements within 3 ppm). Tissue samples were analysed without any pretreatment protocols
Download
92KB
About this article
Title

Discrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by mass spectrometry imaging

Journal

Endokrynologia Polska

Issue

Vol 69, No 1 (2018)

Pages

2-8

Published online

2017-12-20

DOI

10.5603/EP.a2018.0003

Pubmed

29492952

Bibliographic record

Endokrynologia Polska 2018;69(1):2-8.

Keywords

mass spectrometry imaging
papillary thyroid carcinoma
clinical lipidomics
formalin-fixed tissue specimens

Authors

Anna Wojakowska
Laura M. Cole
Mykola Chekan
Katarzyna Bednarczyk
Magdalena Maksymiak
Małgorzata Oczko-Wojciechowska
Barbara Jarząb
Malcolm R. Clench
Joanna Polańska
Monika Pietrowska
Piotr Widlak

References (24)
  1. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Thyroid. 2009; 19: 1159–1165.
  2. DeLellis RA, Lloyd RV, Heitz PU. Pathology and Genetics of Tumours of Endocrine Organs. WHO Classification of Tumours. IARC Press, Lyon 2004: Lyon.
  3. Lloyd RV, Buehler D, Khanafshar E. Papillary thyroid carcinoma variants. Head Neck Pathol. 2011; 5(1): 51–56.
  4. Kakudo K, Kameyama K, Miyauchi A, et al. Introducing the reporting system for thyroid fine-needle aspiration cytology according to the new guidelines of the Japan Thyroid Association. Endocr J. 2014; 61(6): 539–552.
  5. Faquin WC. The thyroid gland: recurring problems in histologic and cytologic evaluation. Arch Pathol Lab Med. 2008; 132(4): 622–632.
  6. Sakorafas GH. Thyroid nodules; interpretation and importance of fine-needle aspiration (FNA) for the clinician - practical considerations. Surg Oncol. 2010; 19(4): e130–e139.
  7. Jelonek K, Pietrowska M, Ros M, et al. Radiation-induced changes in serum lipidome of head and neck cancer patients. Int J Mol Sci. 2014; 15(4): 6609–6624.
  8. Fernandis AZ, Wenk MR. Membrane lipids as signaling molecules. Curr Opin Lipidol. 2007; 18(2): 121–128.
  9. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917): 860–867.
  10. Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res. 2002; 62(21): 6329–6336.
  11. Dória ML, Cotrim Z, Macedo B, et al. Lipidomic approach to identify patterns in phospholipid profiles and define class differences in mammary epithelial and breast cancer cells. Breast Cancer Res Treat. 2012; 133(2): 635–648.
  12. Fernandis AZ, Wenk MR. Lipid-based biomarkers for cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 2009; 877(26): 2830–2835.
  13. Caprioli RM, Farmer TB, Gile J. Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. Anal Chem. 1997; 69(23): 4751–4760.
  14. Schwamborn K, Caprioli RM. Molecular imaging by mass spectrometry--looking beyond classical histology. Nat Rev Cancer. 2010; 10(9): 639–646.
  15. Seeley EH, Caprioli RM. MALDI imaging mass spectrometry of human tissue: method challenges and clinical perspectives. Trends Biotechnol. 2011; 29(3): 136–143.
  16. Clench MR. Advances in mass spectrometry imaging. Proteomics. 2016; 16(11-12): 1605–1606.
  17. Ishikawa S, Tateya I, Hayasaka T, et al. Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer. PLoS One. 2012; 7(11): e48873.
  18. Ryu J. Lipid MALDI MS Profiling Accurately Distinguishes Papillary Thyroid Carcinoma from Normal Tissue. Journal of Proteomics & Bioinformatics. 2013; 06(04).
  19. Guo S, Qiu L, Wang Y, et al. Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Anal Bioanal Chem. 2014; 406(18): 4357–4370.
  20. Guo S, Wang Y, Zhou D, et al. Significantly increased monounsaturated lipids relative to polyunsaturated lipids in six types of cancer microenvironment are observed by mass spectrometry imaging. Sci Rep. 2014; 4: 5959.
  21. Fox CH, Johnson FB, Whiting J, et al. Formaldehyde fixation. J Histochem Cytochem. 1985; 33(8): 845–853.
  22. Hackett MJ, McQuillan JA, El-Assaad F, et al. Chemical alterations to murine brain tissue induced by formalin fixation: implications for biospectroscopic imaging and mapping studies of disease pathogenesis. Analyst. 2011; 136(14): 2941–2952.
  23. Pietrowska M, Gawin M, Polańska J, et al. Tissue fixed with formalin and processed without paraffin embedding is suitable for imaging of both peptides and lipids by MALDI-IMS. Proteomics. 2016; 16(11-12): 1670–1677.
  24. Initializing EM algorithm for univariate Gaussian, multi-component, heteroscedastic mixture models by dynamic programming partitions. arXiv:1506.07450v2 [stat.AP] 2015.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl